MGTA - Magenta Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
-0.57 (-7.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.43
Bid6.75 x 1300
Ask9.00 x 900
Day's Range6.67 - 7.19
52 Week Range5.76 - 18.40
Avg. Volume139,920
Market Cap269.786M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateMar 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.50
  • Business Wire

    Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

    Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights.

  • Did Hedge Funds Drop The Ball On Magenta Therapeutics, Inc. (MGTA) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Magenta Therapeutics, Inc. (MGTA) ?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector

    Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector

    Biotechs represent some of the most difficult to gauge investment opportunities on the Street. This is because shares can make big moves in either direction given a single catalyst, making these stocks more volatile in nature. Having said that, more risk-tolerant investors are constantly being drawn to biotechs as the rewards can be staggering.With investor focus locked in on the space, Goldman Sachs took a closer look at the industry as a whole, writing in a recent note to clients that the landscape is improving.“With healthcare policy and the macro backdrop becoming less of a headwind to the group relative to the concerns that pressured the XBI in late 3Q19, we see fundamentals and stock picking returning to the forefront, supported in part by a recent uptick in M&A activity,” Goldman Sachs' Paul Choi stated.Against this backdrop, Choi reminds investors that not all biotech stocks are bound for greatness. Specifically, he points to 3 names with very different growth prospects, starting coverage on one as a Buy, one as a Hold and the other as a Sell.Bearing this in mind, we used to get the full scoop on the good, the bad and the ugly of the biotech industry. Here’s what we found out.Kiniksa Pharmaceuticals (KNSA)Kiniksa Pharmaceuticals, which just scored an upgrade from Goldman Sachs, wants to meet the large unmet need of patients suffering from autoinflammatory and autoimmune diseases. While shares have fallen year-to-date, Choi argues that the risk/reward profile looks promising ahead of key upcoming catalysts, possibly leading to a reappraisal.Choi highlights its pipeline as a point of strength given the significant unmet need of patients with recurrent pericarditis (RP), giant cell arteritis (GCA) and prurigo nodularis (PN).“While we believe that investors are waiting for clinical de-risking of KNSA’s assets, we recommend positioning in advance of these 2020 events as we anticipate that more value will be assigned to the pipeline upon the data read outs, as we are optimistic regarding KNSA’s sole focus on indications with limited treatment options and comparatively low competitive intensity,” the analyst explained.To top it off, the company is slated to release pivotal Phase 3 data for rilonacept, its most advanced asset, in the second half of 2020. Choi notes that as it received approval for CAPS (cryopyrin-associated periodic syndromes) treatment and the prior Phase 2 data was favorable, “we think investors already view the Phase 3 data and potential approval optimistically and do not view the data as a large inflection point for the stock.”He does however cite KNSA’s mavrilimumab drug for the treatment of giant cell arteritis, an inflammatory disease of blood vessels, as a possible big growth driver given the larger addressable market and commercial opportunity, modelled at about $1.6 billion peak sales opportunity.Based on all that KNSA has going for it, Choi assumed coverage by bumping up the rating from Hold to Buy and attaching an $18 price target. This conveys his confidence in the biotech’s ability to climb 58% higher in the next twelve months.It has been pretty quiet on Wall Street when it comes to other analyst activity. As Choi is the only analyst that has published a recommendation in the last three months, KNSA has a Moderate Buy consensus. (See Kiniksa stock analysis on TipRanks)Magenta Therapeutics (MGTA)Magenta, which uses stem cell biology to develop cures for autoimmune diseases, blood cancers and genetic diseases, is definitely promising thanks to its focus on the curative potential of stem cell transplants as well as on the different stages in the transplant process.Additionally, Magenta stands to add value if it can increase the number of patients that are initially eligible for transplants as it would expand the opportunity long-term. Choi believes that the biotech could achieve this with its earliest stage conditioning program given the amount of addressable patients. These assets include C100 and C300, antibody-drug conjugates (ADCs) for transplant conditioning, or the second step in the stem cell transplant process.“Conditioning toxicity is responsible for up to 10% of mortality following allogeneic transplants and limits the number of patients with successful transplants, and even the number of patients initially eligible for transplant. With a targeted conditioning agent, MGTA hopes to only deplete the cell types required for a successful transplant,” Choi explained. As such, the analyst expects that early data for these programs will attract substantial investor attention.However, Choi points out that its assets are mostly in the early stages and require further clinical validation. “In the near-term we think the early stages of its assets may limit share outperformance, especially without more visibility on the commercial potential in these populations,” he wrote.To this end, Choi took over coverage by issuing a Hold rating and setting an $18 price target. At this target, the potential twelve-month gain comes in at 41%.The rest of the Street’s take is more of a mixed bag. With 2 Buys and 1 Hold, the verdict is that MGTA is a Moderate Buy. However, the average price target of $19 puts the upside potential above Choi’s forecast at 49%. (See Magenta stock analysis on TipRanks)Odonate Therapeutics (ODT)The cancer drug maker represents the “the ugly” of the biotech sector according to Choi.That’s not to say that the Goldman Sachs analyst doesn’t see any positives for Odonate Therapeutics. The company has gained 114% since the start of the year, with Choi adding that its tesetaxel drug in HR+/HER2- metastatic breast cancer appears poised for approval.However, the headwinds facing ODT can’t be ignored. “The HR+/HER2- breast cancer market is competitive with many generic taxane and other chemotherapies currently available, which will likely limit commercial adoption, in our view,” Choi stated.On top of this, he predicts that utilization will primarily be in the patient population evaluated in ODT’s Phase 3 CONTESSA study. This lends itself to Choi’s prediction of sales that are about 60% below consensus estimates, on average, for the first three years following the launch. As a result, the analyst remains bearish.“Given the significant share price appreciation year-to-date, we see the valuation as stretched and look for a more attractive entry point,” Choi concluded.Taking all of this into consideration, Choi initiated his coverage of the biotech with a Sell rating. Given the $26 price target, the four-star analyst sees 14% downside in store.What do other analysts think? Looking at the consensus breakdown, it’s an even split. As 1 Buy and 1 Sell have been received in the last three months, the word on the Street is that ODT is a Hold. In addition, the $26 average stock-price forecast indicates upside potential that’s right in line with Choi’s forecast. (See Odonate stock analysis on TipRanks)

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Benzinga

    The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

    Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...

  • Magenta Therapeutics, Inc. (MGTA) Is Burning These Hedge Funds
    Insider Monkey

    Magenta Therapeutics, Inc. (MGTA) Is Burning These Hedge Funds

    Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]

  • Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Did Magenta Therapeutics, Inc. (NASDAQ:MGTA) Insiders Sell Shares?
    Simply Wall St.

    Did Magenta Therapeutics, Inc. (NASDAQ:MGTA) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Can You Imagine How Magenta Therapeutics's (NASDAQ:MGTA) Shareholders Feel About The 12% Share Price Increase?
    Simply Wall St.

    Can You Imagine How Magenta Therapeutics's (NASDAQ:MGTA) Shareholders Feel About The 12% Share Price Increase?

    It hasn't been the best quarter for Magenta Therapeutics, Inc. (NASDAQ:MGTA) shareholders, since the share price has...

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...

  • Benzinga

    The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...

  • 3 Stocks That Have More Than Tripled So Far in 2019
    Motley Fool

    3 Stocks That Have More Than Tripled So Far in 2019

    Can you guess what these high-flying stocks have in common?

  • Raymond James Thinks Magenta Still Has Upside

    Raymond James Thinks Magenta Still Has Upside

    If a Raymond James analyst is right, Magenta Therapeutics (MGTA) still has upside potential. The investment banking firm's Diane Leone has initiated coverage of the company with an Outperform rating and set a target price of $22, according The Fly. Warning! GuruFocus has detected 5 Warning Signs with AVGO.

  • How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares?
    Simply Wall St.

    How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mentionRead More...